Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress

Thursday, October 12, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, Inc. is set to present at the 30th Annual Congress of the European Society of Gene & Cell Therapy. The company leverages its proprietary ARCUS platform for advanced gene editing therapies, including gene insertion and elimination. This presentation highlights its commitment to innovative gene therapy solutions.
Price reaction · baseline $9.684 (2023-10-11 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
-4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is presenting at a prominent congress.
  • The company is utilizing an innovative gene editing platform.
  • Focus on developing advanced in vivo gene editing therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Oct. 12, 2023– Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination,

Frequently Asked Questions

What is the focus of Precision BioSciences' presentation?

The presentation focuses on their proprietary ARCUS platform for gene editing therapies.

When is the ESGCT 30th Annual Congress?

The ESGCT 30th Annual Congress takes place in October 2023.

What therapies does Precision BioSciences develop?

They develop in vivo gene editing therapies, including gene insertion and elimination.

Where is Precision BioSciences located?

Precision BioSciences is based in Durham, North Carolina.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing ARCUS platform ESGCT
Last updated: Oct 12, 2023

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →